The orally administered PDE-5 inhibitors have become first-line treatment for erectile dysfunction. Although the three currently available PDE-5 inhibitors have shown similar efficacy, tadalafil has a much longer half-life than sildenafil or vardenafil, and the pharmacokinetic profile of tadalafil is not affected by food. However, there is a more immediate response to dosing with sildenafil and vardenafil than tadalafil. As with all drugs, there will be individual variations in response and the physician's skill is in finding the right drug for the right patient.
Kirby M.ED as a marker for cardiovascular disease. Br J Diabetes Vasc Dis2002;2:239-41.
2.
Feldman HA, Goldstein I., Hatzichristou DG, Krane RJ, McKinlay JBImpotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol1994;151:54-61.
3.
McCulloch DK , Campbell IV, Wu FC et al. The prevalence of diabeti impotence . Diabetologia1980;18:279-83.
4.
Eardley I.Pathophysiology of erectile dysfunction. Br J Diabetes Vasc Dis2002;2:272-6.
5.
Ali W., Besarani D., Kirby R.Modern treatment of erectile dysfunction. Br J Diabetes Vasc Dis2002;2:255-61.
6.
Nichols DJ, Muirhead GJ, Harness JAPharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, U food effects and dose proportionality. Br J Clin Pharmacol2002 D ;53(suppl 1):55-125.
7.
Rajagopalan P., Mazzu A., Xia C., Dawkins R., Sundaresan P.Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol2003;43:260-7.
8.
Patterson D., Bedding A., Jewell H., Payne C., Mitchell MIThe effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). 4th Congress of the European Society for Sexual and Impotence Research (ESSIR), 2001; Rome, Italy.
9.
Moore R., Edwards J., McQuay H.Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol2002;2:6.
10.
Porst H., Rosen R., Padma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res2001;13:192-9.
11.
Hellstrom WJ , Gittelman M., Karlin G. et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl2002;23:763-71.
12.
Hellstrom WJ , Gittelman M., Karlin G. et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology2003;61:8-14.
13.
Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol2002;168:1332-6.
14.
Goldstein I. , Lue TF, Padma-Nathan H., Rosen RC, Steers WD, Wicker PAOral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med1998;338:1397-404.
15.
Montorsi F. , McDermott TE, Morgan R. et al. Efficacy and safety of fixeddose oral sildenafil in the treatment of erectile dysfunction of various etiologies . Urology1999;53:1011-18.
16.
Hellstrom WJ , Overstreet JW, Yu A. et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol2003;170:887-91.
17.
Saenz de Tejada I., Angulo J., Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil . Int J Impot Res2001;13:282-90.
18.
Jackson G.Cardiovascular safety in erectile dysfunction treatment. Br J Diabetes Vasc Dis2002;4:301-04.
19.
Rosen RC, McKenna KEPDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res2002; 13:36-88.
20.
Cheitlin MD , Hutter AM, Jr., Brindis RG et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation1999;99:168-77.
21.
DeBusk R., Drory Y., Goldstein I. et al. management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. Am J Cardiol2000;86:175-81.
